STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

VRTX VERTEX PHARMACEUTICALS INCORPORATED StockScouter® Report

5

StockScouter® Score

VERTEX PHARMACEUTICALS INCORPORATED, a large cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is above average. Positive/Neutral
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for VRTX. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Short-term relative price momentum exhibits moderate weakness. Neutral/Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 20% done.
Progress: 80% done.
Low
High

Core Model Grades

A
C
F
B

Previous Ratings

6
6
5